-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Fulcrum Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q3 2024.
- Fulcrum Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$25.1M, a 8.43% increase year-over-year.
- Fulcrum Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$30.5M, a 72.5% increase year-over-year.
- Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$111M, a 1.69% increase from 2022.
- Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$113M, a 38.9% decline from 2021.
- Fulcrum Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$81.1M, a 13.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)